AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT103.21+0.11 (+0.11%) ▲|ACN245.06+9.90 (+4.21%) ▲|ADBE247.73-0.64 (-0.26%) ▼|AMAT413.18+17.25 (+4.36%) ▲|AMD566.94+6.68 (+1.19%) ▲|AMGN449.95+2.00 (+0.45%) ▲|AMT177.77-6.07 (-3.30%) ▼|AMZN252.54-0.56 (-0.22%) ▼|AVGO347.23+4.90 (+1.43%) ▲|AXP316.12+3.21 (+1.02%) ▲|BA166.71-1.47 (-0.87%) ▼|BAC51.08+0.40 (+0.79%) ▲|BKNG148.00-2.15 (-1.43%) ▼|BLK1,150.65+14.60 (+1.29%) ▲|BMY60.42-1.13 (-1.84%) ▼|BNY148.96+1.38 (+0.94%) ▲|BRK-B544.11+1.12 (+0.21%) ▲|C124.09+1.40 (+1.14%) ▲|CAT715.96+2.65 (+0.37%) ▲|CL91.91-0.26 (-0.28%) ▼|CMCSA21.68-0.17 (-0.76%) ▼|COF204.41+0.97 (+0.47%) ▲|COP150.26+2.30 (+1.55%) ▲|COST983.47-8.67 (-0.87%) ▼|CRM240.71-0.18 (-0.07%) ▼|CSCO109.93-1.45 (-1.30%) ▼|CVS90.66-0.47 (-0.52%) ▼|CVX231.27+3.04 (+1.33%) ▲|DE640.21+0.63 (+0.10%) ▲|DHR234.37+2.37 (+1.02%) ▲|DIS109.14-1.09 (-0.99%) ▼|DUK124.73-0.07 (-0.06%) ▼|EMR167.49+1.22 (+0.73%) ▲|FDX301.65-5.45 (-1.77%) ▼|GD354.34-0.55 (-0.16%) ▼|GE303.32+5.66 (+1.90%) ▲|GEV890.28-4.80 (-0.54%) ▼|GILD159.23+0.15 (+0.09%) ▲|GM81.11+0.57 (+0.71%) ▲|GOOG320.44+3.61 (+1.14%) ▲|GOOGL323.80+3.22 (+1.00%) ▲|GS923.33+11.56 (+1.27%) ▲|HD318.52+0.02 (+0.01%) ▲|HON219.28+0.47 (+0.21%) ▲|IBM251.45+1.20 (+0.48%) ▲|INTC93.80+0.06 (+0.06%) ▲|INTU330.13+1.68 (+0.51%) ▲|ISRG447.28+1.40 (+0.31%) ▲|JNJ270.25+1.52 (+0.57%) ▲|JPM339.65+3.86 (+1.15%) ▲|KO91.83+0.65 (+0.71%) ▲|LIN508.40-0.25 (-0.05%) ▼|LLY1,286.30+4.39 (+0.34%) ▲|LMT629.32+6.33 (+1.02%) ▲|LOW198.75+0.57 (+0.29%) ▲|LRCX254.12+13.27 (+5.51%) ▲|MA613.49+3.64 (+0.60%) ▲|MCD251.60+2.13 (+0.85%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.87+0.92 (+0.98%) ▲|META613.34-6.85 (-1.10%) ▼|MMM172.23+0.65 (+0.38%) ▲|MO73.48-0.01 (-0.01%) ▼|MRK140.34-1.49 (-1.05%) ▼|MS189.48+2.57 (+1.38%) ▲|MSFT528.46-2.88 (-0.54%) ▼|MU972.96+44.20 (+4.76%) ▲|NEE81.95-0.47 (-0.57%) ▼|NFLX61.76-0.76 (-1.22%) ▼|NKE37.26-0.30 (-0.80%) ▼|NOW150.63-4.15 (-2.68%) ▼|NVDA217.08-0.87 (-0.40%) ▼|ORCL130.98+0.45 (+0.34%) ▲|PEP132.30-1.20 (-0.90%) ▼|PFE29.38-0.43 (-1.43%) ▼|PG159.22-0.01 (-0.01%) ▼|PLTR194.37-4.36 (-2.19%) ▼|PM202.89+0.27 (+0.13%) ▲|QCOM181.52-2.66 (-1.44%) ▼|RTX197.12+2.52 (+1.30%) ▲|SBUX104.33+1.29 (+1.25%) ▲|SCHW88.86-0.44 (-0.49%) ▼|SO92.58-0.07 (-0.08%) ▼|SPG212.19-0.10 (-0.04%) ▼|T21.04+0.10 (+0.45%) ▲|TMO700.50+7.48 (+1.08%) ▲|TMUS146.74-0.09 (-0.06%) ▼|TSLA401.00-6.46 (-1.59%) ▼|TXN305.50-3.41 (-1.10%) ▼|UBER65.57-0.21 (-0.32%) ▼|UNH412.43+2.04 (+0.50%) ▲|UNP301.70+1.82 (+0.61%) ▲|UPS104.89-1.20 (-1.13%) ▼|USB59.65-0.10 (-0.16%) ▼|V401.72-0.15 (-0.04%) ▼|VZ43.76-0.18 (-0.40%) ▼|WFC84.38+1.72 (+2.07%) ▲|WMT118.74-0.58 (-0.49%) ▼|XOM183.42+3.51 (+1.95%) ▲|AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT103.21+0.11 (+0.11%) ▲|ACN245.06+9.90 (+4.21%) ▲|ADBE247.73-0.64 (-0.26%) ▼|AMAT413.18+17.25 (+4.36%) ▲|AMD566.94+6.68 (+1.19%) ▲|AMGN449.95+2.00 (+0.45%) ▲|AMT177.77-6.07 (-3.30%) ▼|AMZN252.54-0.56 (-0.22%) ▼|AVGO347.23+4.90 (+1.43%) ▲|AXP316.12+3.21 (+1.02%) ▲|BA166.71-1.47 (-0.87%) ▼|BAC51.08+0.40 (+0.79%) ▲|BKNG148.00-2.15 (-1.43%) ▼|BLK1,150.65+14.60 (+1.29%) ▲|BMY60.42-1.13 (-1.84%) ▼|BNY148.96+1.38 (+0.94%) ▲|BRK-B544.11+1.12 (+0.21%) ▲|C124.09+1.40 (+1.14%) ▲|CAT715.96+2.65 (+0.37%) ▲|CL91.91-0.26 (-0.28%) ▼|CMCSA21.68-0.17 (-0.76%) ▼|COF204.41+0.97 (+0.47%) ▲|COP150.26+2.30 (+1.55%) ▲|COST983.47-8.67 (-0.87%) ▼|CRM240.71-0.18 (-0.07%) ▼|CSCO109.93-1.45 (-1.30%) ▼|CVS90.66-0.47 (-0.52%) ▼|CVX231.27+3.04 (+1.33%) ▲|DE640.21+0.63 (+0.10%) ▲|DHR234.37+2.37 (+1.02%) ▲|DIS109.14-1.09 (-0.99%) ▼|DUK124.73-0.07 (-0.06%) ▼|EMR167.49+1.22 (+0.73%) ▲|FDX301.65-5.45 (-1.77%) ▼|GD354.34-0.55 (-0.16%) ▼|GE303.32+5.66 (+1.90%) ▲|GEV890.28-4.80 (-0.54%) ▼|GILD159.23+0.15 (+0.09%) ▲|GM81.11+0.57 (+0.71%) ▲|GOOG320.44+3.61 (+1.14%) ▲|GOOGL323.80+3.22 (+1.00%) ▲|GS923.33+11.56 (+1.27%) ▲|HD318.52+0.02 (+0.01%) ▲|HON219.28+0.47 (+0.21%) ▲|IBM251.45+1.20 (+0.48%) ▲|INTC93.80+0.06 (+0.06%) ▲|INTU330.13+1.68 (+0.51%) ▲|ISRG447.28+1.40 (+0.31%) ▲|JNJ270.25+1.52 (+0.57%) ▲|JPM339.65+3.86 (+1.15%) ▲|KO91.83+0.65 (+0.71%) ▲|LIN508.40-0.25 (-0.05%) ▼|LLY1,286.30+4.39 (+0.34%) ▲|LMT629.32+6.33 (+1.02%) ▲|LOW198.75+0.57 (+0.29%) ▲|LRCX254.12+13.27 (+5.51%) ▲|MA613.49+3.64 (+0.60%) ▲|MCD251.60+2.13 (+0.85%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.87+0.92 (+0.98%) ▲|META613.34-6.85 (-1.10%) ▼|MMM172.23+0.65 (+0.38%) ▲|MO73.48-0.01 (-0.01%) ▼|MRK140.34-1.49 (-1.05%) ▼|MS189.48+2.57 (+1.38%) ▲|MSFT528.46-2.88 (-0.54%) ▼|MU972.96+44.20 (+4.76%) ▲|NEE81.95-0.47 (-0.57%) ▼|NFLX61.76-0.76 (-1.22%) ▼|NKE37.26-0.30 (-0.80%) ▼|NOW150.63-4.15 (-2.68%) ▼|NVDA217.08-0.87 (-0.40%) ▼|ORCL130.98+0.45 (+0.34%) ▲|PEP132.30-1.20 (-0.90%) ▼|PFE29.38-0.43 (-1.43%) ▼|PG159.22-0.01 (-0.01%) ▼|PLTR194.37-4.36 (-2.19%) ▼|PM202.89+0.27 (+0.13%) ▲|QCOM181.52-2.66 (-1.44%) ▼|RTX197.12+2.52 (+1.30%) ▲|SBUX104.33+1.29 (+1.25%) ▲|SCHW88.86-0.44 (-0.49%) ▼|SO92.58-0.07 (-0.08%) ▼|SPG212.19-0.10 (-0.04%) ▼|T21.04+0.10 (+0.45%) ▲|TMO700.50+7.48 (+1.08%) ▲|TMUS146.74-0.09 (-0.06%) ▼|TSLA401.00-6.46 (-1.59%) ▼|TXN305.50-3.41 (-1.10%) ▼|UBER65.57-0.21 (-0.32%) ▼|UNH412.43+2.04 (+0.50%) ▲|UNP301.70+1.82 (+0.61%) ▲|UPS104.89-1.20 (-1.13%) ▼|USB59.65-0.10 (-0.16%) ▼|V401.72-0.15 (-0.04%) ▼|VZ43.76-0.18 (-0.40%) ▼|WFC84.38+1.72 (+2.07%) ▲|WMT118.74-0.58 (-0.49%) ▼|XOM183.42+3.51 (+1.95%) ▲|
13.7 C
New York
Wednesday, October 28, 2026

Tag: malignancy

newsFORsourcecompanycontentinformation1releasesmarket

TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026

Poster highlights durable disease control, acceptable tolerability and exploratory evidence of treatment-associated antitumor immune activity in patients with advanced solid tumorsBOSTON, Oct. 26, 2026 /PRNewswire/...

Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented...

HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 25, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in...

Pathological complete response (pCR) achieved in the breast (ypT0/Tis) and affected lymph nodes (ypN0) in 5 out of 7 patients (71%; 95% CI 29-96%)...

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ®...

Cancer Diagnostics Market to Reach US$ 41.5 Billion by 2031 at 7.2% CAGR, says Wissen Research

Sheridan, WY, Oct. 15, 2026 /PRNewswire/ -- The global cancer diagnostics market is valued at USD 29.3 billion in 2026 and is projected to reach...

Cancer Diagnostics Market to Reach US$ 41.5 Billion by 2031 at 7.2% CAGR, says Wissen Research

SHERIDAN, Wyo., Oct. 15, 2026 /PRNewswire/ -- The global cancer diagnostics market is valued at USD 29.3 billion in 2026 and is projected to reach...

Legacy Healthcare’s CINAINU® Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older

EPALINGES, Switzerland, Oct. 13, 2026 /PRNewswire/ -- Legacy Healthcare, a biopharmaceutical company developing innovative botanical prescription drugs, today announced that the U.S. Food and...

Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn’s Disease and Ulcerative Colitis at ACG 2026

New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely...

TransCode Therapeutics Announces Leadership Transition

Tom Fitzgerald, Chief Financial Officer, Announces his RetirementJohn Tattory, to become Interim Chief Financial OfficerBOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:...

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMalignancy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers